China NMPA Approves Tagitanlimab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#TagitanlimabInjection #Tagitanlimab #Ketaille #NMPAApproval #NasopharyngealCancer #NPC #Immunotherapy #PDL1 #MonoclonalAntibody #KelunBiotech

China’s NMPA Approves Zolbetuximab for Injection

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Zolbetuximab
#Wiluyi
#CLDN182
#GastricCancer
#GEJCancer
#Astellas
#NMPAApproval
#Oncology
#TargetedTherapy
#MonoclonalAntibody

Approval of Ongericimab Injection by China NMPA

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPAApproval #OngericimabInjection #JunshiBiosciences #PCSK9Inhibitor #CholesterolTreatment #Hyperlipidemia #InnovativeMedicine #ChinaBiopharma

China NMPA Approves Ebronucimab Injection for Hypercholesterolemia Treatment

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Ebronucimab #PCSK9Inhibitor #CholesterolTreatment #NMPAApproval #ChineseBiologics #Hypercholesterolemia #CardiovascularHealth #KangrongDongfang

China NMPA Approves Icodec Insulin Injection(Awiqli) for Market Launch

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#InsulinIcodec
#Awiqli
#NovoNordisk
#NMPAApproval
#ChinaDrugAdministration
#Type2Diabetes
#LongActingInsulin
#DiabetesTreatment
#PharmaceuticalNews
#2024DrugApprovals

🎉 NMPA Approval!
#Bireociclib Tablets (#Xuan Yuening) by #Xuanzhu Biopharmaceutical Co., Ltd. are now approved for HR+/HER2– advanced or metastatic breast cancer.

📧 info@dengyuemed.com
#CDK46Inhibitor #HRPositiveBreastCancer #HER2NegativeBreastCancer #NMPAApproval
#HongKongDengYueMedicine

📢 Breaking News!
The NMPA has conditionally approved #Lisaftoclax Tablets 💊—an innovative drug by Suzhou Ascentage Pharma Company Limited.

📎 Learn more: dengyuemed.com/product/asce...

📧 info@dengyuemed.com
#AscentagePharma #NMPAApproval #CLL #SLL #BTKInhibitor
#HongKongDengYueMedicine